How the Justice Department is becoming more forgiving in its FARA crackdown politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
The Rising prevalence of cancer and continuous technological advancements in radiotherapy are the major factors driving the growth of this market. Adding to this, the rising number of conferences and symposia focusing on the advancements in radiotherapy , growing adoption of radiotherapy procedures for cancer treatment and increasing government initiatives and programs are some of the other major factors driving the growth of this radiotherapy market.
The after loaders subsegment of Internal Beam Radiotherapy products to hold the highest growth in the forecast period
The Internal Beam Radiotherapy segment is further classified into seeds, applicators, after loaders, and electronic brachytherapy products. The highest growth amongst the Internal beam radiotherapy or brachytherapy products is expected to be attained by afterloaders in the forecast period. An afterloader guides clinicians to position the radioactive source in a needle, catheter, or tumor-specific applicator. Different
Radiotherapy Market worth $7.3 billion by 2026 - Exclusive Report by MarketsandMarkets Radiotherapy Market by Product (LINAC, CyberKnife, Gamma Knife, Tomotherapy, Particle Therapy, Cyclotron), Procedure (External (IMRT, IGRT, 3D-CRT) Internal (LDR, HDR)), Application (Prostate, Breast, Lung), End User (Hospitals) - Global Forecasts to 2026 , published by MarketsandMarkets, the market is valued at USD 5.9 billion in 2021 and is expected to reach USD 7.3 billion by 2026, at a CAGR of 4.2% during the forecast period.
Browse in-depth TOC on Radiotherapy Market
207 - Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=567
The Rising prevalence of cancer and continuous technological advancements in radiotherapy are the major factors driving the growth of this market. Adding to this, the rising number of conferences and symposia focusing on the advancements in radiotherapy , growing adoption of radiotherapy procedures for cancer treatment and inc
Share:
Exicure, Inc. (NASDAQ:XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced the appointments of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors. We are pleased to welcome Betsy and Andrew to our Board at a critical time for Exicure, having made significant progress with the development of cavrotolimod in oncology and XCUR-FXN in Friedreich s ataxia. Betsy s distinguished career and significant clinical development experience and Andrew s financial and institutional investor experience will provide important perspective to our Board, said Timothy P. Walbert, Exicure s Chairman of the Board of Directors. We look forward to the collective experience they will bring as Exicure advances its pipeline of innovative investigational therapies and we look to deliver on the promise of Exicure s proprietary Spherical Nucleic Acid, or SNA technology.